Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7ofatumumab 4ibrutinib 4Rituximab 2KW-2478 2Dasatinib 2Alemtuzumab 2ziconotide 1sodium luminolate 1ruxolitinib 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fludarabine 1fenebrutinib 1baricitinib 1abexinostat 1Saline Solution 1Lenalidomide 1Hsp90 inhibitor KU757 1Etanercept 1Cyclophosphamide 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × sodium luminolate × Lymphoid × Clear all
NCT02908347 2019-01-23

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

MetrioPharm AG

Phase 2 Completed
46 enrolled 24 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡